AGENNIX AG

EANS-News: AGENNIX AG
Agennix Schedules Conference Call on November 3 to Discuss Third Quarter of 2011 Financial Results

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
quarterly report


Planegg/Munich (Germany), Princeton, NJ and Houston, TX, October 27, 2011 (euro
adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) announced today that the
Company will hold a conference call to discuss financial results for the third
quarter of 2011 and to provide a business update. The results will be published
on Thursday, November 3, 2011, in advance of the conference call. 

The conference call, which will be conducted in English, will be held on
Thursday, November 3, 2011 at 9 AM ET/2 PM CET.

A live webcast will be available on the Agennix Web site at www.agennix.com. A
replay will be available via the Web site following the live event. 

Dial-in numbers for the call are as follows:

Participants from Europe:       0049 (0)69 710445598            
                        0044 (0)20 3003 2666
Participants from the U.S.:     1-212 999 6659 

Please dial in 10 minutes before the beginning of the conference call.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company's most advanced program is talactoferrin, an
oral immunotherapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer and in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in non-small
cell lung cancer and in a Phase II/III trial in severe sepsis. Other clinical
development programs include RGB-286638, a multi-targeted kinase inhibitor in
Phase I testing, and a topical gel form of talactoferrin for diabetic foot
ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has
three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix Web site at
www.agennix.com.

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. The achievement of
positive results in early stage clinical studies does not ensure that later
stage or large scale clinical studies will be successful.  Even if the results
from our later stage trials with talactoferrin, including the ongoing FORTIS-M
trial in non-small cell lung cancer, are considered positive, there can be no
guarantee that they will be sufficient to gain marketing approval in the United
States or any other country, and regulatory authorities may require additional
information, data and/or further pre-clinical or clinical studies to support
approval. In such event, there can be no guarantee that the Company will have or
be able to obtain the financial resources to conduct any such additional studies
or that such studies will yield results sufficient for approval. Forward-looking
statements speak only as of the date on which they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.

Agennix(TM) is a trademark of the Agennix group.


Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications 		
Phone: +49 (0)89 8565 2693		
ir@agennix.com
		
In the U.S.: Laurie Doyle		
Senior Director, Investor Relations & Corporate Communications		
Phone: +1 609 524 5884 	 	
laurie.doyle@agennix.com
	
Additional media contact for Europe:	
MC Services AG	
Raimund Gabriel	
Phone: +49 (0) 89 210 228 0	
raimund.gabriel@mc-services.eu
	
Additional investor contact for Europe:	
Trout International LLC	
Lauren Williams, Vice President	
Phone: +44 207 936 9325 	
lwilliams@troutgroup.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     AGENNIX AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 89 8565 2693
FAX:         +49 89 8565 2610
mail:     ir@agennix.com
WWW:      http://www.agennix.com
sector:      Pharmaceuticals
ISIN:        DE000A1A6XX4
indexes:     CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Düsseldorf, Hannover, München 
language:   English
 



Weitere Meldungen: AGENNIX AG

Das könnte Sie auch interessieren: